---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-012322"
form_type: "8-K"
ticker: "IKT"
cik: "0001750149"
company_name: "Inhibikase Therapeutics, Inc."
filed_at: "2022-06-29T23:59:59+00:00"
generated_at: "2026-06-24T22:25:38.563054+00:00"
event_type: "other"
sentiment: "negative"
materiality_score: 0.3
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Inhibikase Therapeutics 2022 Annual Meeting results: share count increase fails

## Summary
- Directors Roy Freeman and Paul Grint elected with ~11.4M and ~11.5M votes for; ~4.5M broker non-votes.
- Ratification of CohnReznick LLP as auditor approved: 16.4M for, 31.5K against, 56.6K abstain.
- Proposal to increase authorized shares from 100M to 200M failed: 15M for, 1.4M against, not meeting required percentage.

## SEC filing metadata
- accession: 0000950170-22-012322
- form_type: 8-K
- ticker: IKT
- cik: 0001750149
- company_name: Inhibikase Therapeutics, Inc.
- filed_at: 2022-06-29T23:59:59+00:00
- event_type: other
- sentiment: negative
- materiality_score: 0.3
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750149/000095017022012322/0000950170-22-012322-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750149/000095017022012322/ikt-20220624.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-012322
- JSON: https://secwatch.observer/filing/0000950170-22-012322.json
- Plain text: https://secwatch.observer/filing/0000950170-22-012322.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.